EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50%-Reference-Cited by-同舟云学术

EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50%

Published:2017 Issue: Volume:22 Page:7-10
ISSN:2213-0071
Container-title:Respiratory Medicine Case Reports
language:en
Short-container-title:Respiratory Medicine Case Reports

Author:

Zarogoulidis Paul,Chinelis Panos,Efthymiou Christofors,Athanasiadou Anastasia,Mpikos Vasilis,Papatsibas George,Papadopoulos Vasilis,Maragouli Elena,Huang Haidong,Trakada Georgia^ORCID,Kallianos Anastasios,Veletza Lemonia,Hohenforst-Schmidt Wolfgang

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference16 articles.

1. Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy;Domvri;J. Cancer,2013

2. Treatment of non-small cell lung cancer (NSCLC);Zarogoulidis;J. Thorac. Dis.,2013

3. Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy;Domvri;Transl. Lung Cancer Res.,2013

4. Tissue is the issue and tissue competition. Re-biopsy for mutation T790: where and why?;Zarogoulidis;Clin. Transl. Med.,2017

5. Liquid biopsy: detection of molecular markers for treatment decisions in lung cancer;Bruckl;Pneumologie,2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cryobiopsy for pneumonitis diagnosis in NSCLC immunotherapy;Respiratory Medicine Case Reports;2022

2. EBUS-TNBA 22G samples: Comparison of PD-L1 expression between DAKO and BIOCARE®;Journal of Cancer;2019

3. Transformation of ALK expression and PD-L1 0% to PD-L1 90% only after surgery: the need for rebiopsy in lung cancer patients;International Medical Case Reports Journal;2019-01

4. Afatinib;Reactions Weekly;2017-07

5. Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment;Respiratory Medicine Case Reports;2017